NDC 26436-5027-2
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 26436-5027-2
- Product root
- 26436-5027
- Identity scope
- Package
- Primary current NDC product row
- Not present
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2025-2 | 2026-08-02 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2025-1 | 2025-09-25 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2025-1 | 2026-08-01 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2024-2 | 2025-09-25 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2024-2 | 2026-08-01 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2024-1 | 2025-09-25 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2024-1 | 2026-08-01 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-2 | 2025-09-25 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-2 | 2026-08-01 |
| compounder | package | 26436-5027 | 26436-5027-2 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-08-01 |
Compounder NDC reports#
| Establishment | FEI | Product NDC | Package NDC | Product | Active ingredients | Reporting period | Normalization |
|---|---|---|---|---|---|---|---|
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2025-2 | valid |
| Hybrid Pharma | 26436-5027 | 26436-5027-2 | Alpha Lipoic acid 25mg/mL | 25 mg/1 mL | 2025-1 | valid | |
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2025-1 | valid |
| Hybrid Pharma | 26436-5027 | 26436-5027-2 | Alpha Lipoic acid 25mg/mL | 25 mg/1 mL | 2024-2 | valid | |
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2024-2 | valid |
| Hybrid Pharma | 26436-5027 | 26436-5027-2 | Alpha Lipoic acid 25mg/mL | 25 mg/1 mL | 2024-1 | valid | |
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2024-1 | valid |
| Hybrid Pharma | 26436-5027 | 26436-5027-2 | Alpha Lipoic acid 25mg/mL | 25 mg/1 mL | 2023-2 | valid | |
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2023-2 | valid |
| Hybrid Pharma | 079665742 | 26436-5027 | 26436-5027-2 | Alpha Lipoic Acid | 25 mg/1 mL | 2023-1 | valid |